| Nivolumab in Previously Untreated Melanoma without BRAF Mutation C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ... New England journal of medicine 372 (4), 320-330, 2015 | 6102 | 2015 |
| Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ... Journal of Clinical Oncology 35 (2), 226-235, 2017 | 573 | 2017 |
| Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial PA Ascierto, GV Long, C Robert, B Brady, C Dutriaux, AM Di Giacomo, ... JAMA oncology 5 (2), 187-194, 2019 | 350 | 2019 |
| Subarachnoid hemorrhage: a preventable disease with a heritable component BM Kissela, L Sauerbeck, D Woo, J Khoury, J Carrozzella, A Pancioli, ... Stroke 33 (5), 1321-1326, 2002 | 346 | 2002 |
| Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL C Aspord, MT Leccia, J Charles, J Plumas Cancer immunology research 1 (6), 402-415, 2013 | 181 | 2013 |
| Anti-PD1-induced psoriasis: a study of 21 patients. J Bonigen, C Raynaud‐Donzel, J Hureaux, N Kramkimel, A Blom, ... Journal of the European Academy of Dermatology & Venereology 31 (5), 2017 | 174 | 2017 |
| Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma C Robert, GV Long, B Brady, C Dutriaux, AM Di Giacomo, L Mortier, ... Journal of Clinical Oncology 38 (33), 3937-3946, 2020 | 173 | 2020 |
| Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial) C Verry, S Dufort, J Villa, M Gavard, C Iriart, S Grand, J Charles, ... Radiotherapy and Oncology 160, 159-165, 2021 | 100 | 2021 |
| Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor J Charles, J Di Domizio, D Salameire, N Bendriss-Vermare, C Aspord, ... Journal of Investigative Dermatology 130 (6), 1646-1656, 2010 | 94 | 2010 |
| Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms A Emadali, N Hoghoughi, S Duley, A Hajmirza, E Verhoeyen, FL Cosset, ... Blood, The Journal of the American Society of Hematology 127 (24), 3040-3053, 2016 | 76 | 2016 |
| Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization C Aspord, L Tramcourt, C Leloup, JP Molens, MT Leccia, J Charles, ... Journal of investigative dermatology 134 (10), 2551-2561, 2014 | 74 | 2014 |
| Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer J Charles, L Chaperot, D Salameire, J Di Domizio, C Aspord, R Gressin, ... European Journal of Dermatology: EJD 20 (1), 16, 2010 | 73 | 2010 |
| A novel cancer vaccine strategy based on HLA-A* 0201 matched allogeneic plasmacytoid dendritic cells C Aspord, J Charles, MT Leccia, D Laurin, MJ Richard, L Chaperot, ... PloS one 5 (5), e10458, 2010 | 69 | 2010 |
| Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients O Epaulard, C Saint-Raymond, C Villier, J Charles, N Roch, JC Beani, ... Clinical Microbiology and Infection 16 (9), 1362-1364, 2010 | 58 | 2010 |
| Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation J Charles, JC Beani, G Fiandrino, B Busser Journal of the American Academy of Dermatology 71 (3), e97-e99, 2014 | 55 | 2014 |
| Plasma circulating tumor DNA levels for the monitoring of melanoma patients: landscape of available technologies and clinical applications B Busser, J Lupo, L Sancey, S Mouret, P Faure, J Plumas, L Chaperot, ... BioMed Research International 2017 (1), 5986129, 2017 | 54 | 2017 |
| An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial J Charles, L Chaperot, D Hannani, J Bruder Costa, I Templier, S Trabelsi, ... Oncoimmunology 9 (1), 1738812, 2020 | 51 | 2020 |
| HLA-A* 0201+ plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients C Aspord, MT Leccia, D Salameire, D Laurin, L Chaperot, J Charles, ... Journal of investigative dermatology 132 (10), 2395-2406, 2012 | 46 | 2012 |
| The features of circulating and tumor-infiltrating γδ T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome P Girard, J Charles, C Cluzel, E Degeorges, O Manches, J Plumas, ... Oncoimmunology, 2019 | 41 | 2019 |
| Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses R Ghinnagow, J De Meester, LJ Cruz, C Aspord, S Corgnac, ... Oncoimmunology 6 (9), e1339855, 2017 | 41 | 2017 |
